We are PanCAD.ai, a Taiwan-based company built on NTU research and focused on supporting earlier pancreatic cancer detection.
Pancreatic cancer can be difficult to detect early, and late diagnosis remains a major challenge. AI-assisted review may help radiologists identify suspicious findings while lesions are small; clinical decisions remain with the care team.
Every product decision starts with a patient-centered question: “Does it help patients?”
We support claims with published literature and applicable regulatory documentation. Clear, accurate data respects medical partners.
AI does not replace physicians; it provides additional information for radiology and gastroenterology teams.
Prof. Wei-Chung Wang (NTU) and Prof. Wei-Chih Liao (NTUH) launch AI research for early pancreatic cancer imaging
NTU research team begins multicenter clinical validation
PanCAD.ai Co., Ltd. founded; technology licensed for commercialization
Taiwan’s first RSNA Margulis Award; SNQ, Taipei BioTech, and National Innovation Awards
FDA Breakthrough Device Designation; TFDA medical device license No. 007946
Used across medical centers, regional hospitals, and health centers, with cumulative use in more than 5,500 patient cases across research and commercial applications
PANCREASaver® grew from long-term research at NTU and NTU Hospital — an AI-assisted medical device focused on earlier pancreatic cancer detection.
Technical founder and principal investigator for AI-assisted pancreatic lesion detection
Clinical validation lead — prospective, multicenter studies in real-world settings
Commercialization — translating research into clinical software
From deep learning and radiomics to prediagnostic CT, these studies document the team’s research foundation. Consult each original paper for its study population and scope.
Diagnostic and Interventional Imaging, 107(7–8):265–275, 2026.
DOI: 10.1016/j.diii.2026.01.007